GRF Spain: Madrid


    GRF ES
    Last Updated: Sep 9, 2022 5:38 p.m. CEDT Delayed quote


    0.60 5.05%
    Previous Close
    Advanced Charting
    Volume: 1.68M 65 Day Avg: 982.31K
    171% vs Avg
    11.92 Day Range 12.66
    11.26 52 Week Range 22.64

    Your Watchlists

    Customize 江湖电竞最新版比赛(江湖电竞投注app网站)

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    GRF Overview

    Key Data

    • Open €11.94
    • Day Range 11.92 - 12.66
    • 52 Week Range 11.26 - 22.64
    • Market Cap €7.07B
    • Shares Outstanding N/A
    • Public Float 291.77M
    • Beta N/A
    • Rev. per Employee €212.22K
    • P/E Ratio N/A
    • EPS N/A
    • Yield 0.00%
    • Dividend €0.30
    • Ex-Dividend Date Jun 3, 2021
    • Short Interest N/A
    • % of Float Shorted N/A
    • Average Volume 982.31K


    5 Day
    • 5.50%
    1 Month
    • -9.34%
    3 Month
    • -31.65%
    • -26.10%
    1 Year
    • -39.11%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 3 Full Ratings

    Recent News

    Read full story

    These European companies benefit from high health-care prices in the U.S.

    Read full story

    Seek cover in European stocks if Fed hikes rates, says Deutsche Bank

    Read full story

    Strong Chinese data lift European markets

    Novartis sells diagnostics unit for $1.68 billion

    LONDON (江湖电竞最新版比赛(江湖电竞投注app网站)) -- Novartis AG has agreed to sell its blood-transfusion diagnostics unit to Spain's Grifols SA for $1.675 billion in cash, the Swiss pharmaceutical giant said Monday. "The sale ... enables us to focu...

    Read full story

    Banks boost Europe stocks after mixed U.S. data

    Europe edges higher after bin Laden’s death

    Danisco surges on higher DuPont offer; TNT down after results

    Europe ends lower for second straight session

    European equity benchmarks trade lower to start the week, extending losses from the previous session, with miners notably weaker as investors fret about global economic-growth trends.

    Grifols to acquire Talecris for $3.4 billion

    Spain’s Grifols SA to acquire Talecris Biotherapeutics Holdings Corp. for $3.4 billion, forming a global producer of plasma protein therapies.

    New Grifols shares in Talecris deal are non-voting

    Talecris shares closed Friday at $15.92

    Grifols to pay indicated $26.16 per Talecris share

    Grifols to pay $19, 0.641 share per Talecris share

    Talecris to be acquired by Grifols for $3.4B

    Read full story

    Banco Santander, Inditex among top holds for U.S. funds

    No Headlines Available

    Grifols S.A.

    Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.


    Name Chg % Market Cap
    Baxter International Inc. 0.31% CHF35.47B
    Almirall S.A. 2.98% €1.62B